The effects of AER and eGFR on outcomes of CVD in patients with T2DM in an urban community over 8 years of multifactorial treatment: the Beijing Communities Diabetes Study 18
机构:[1]Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China临床科室内分泌科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Medical Records and Statistics Department, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China[3]Clinical and Translational Science Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA[4]Department of General Practice, Jinsong Community Health Service Center, Beijing, People’s Republic of China[5]Department of General Practice, Cuigezhuang Community Health Service Center, Beijing, People’s Republic of China[6]Department of General Practice, Xinjiekou Community Health Service Center, Beijing, People’s Republic of China[7]Department of General Practice, Yuetan Community Health Service Center of Fuxing Hospital, Capital Medical University, Beijing, People’s Republic of China[8]Department of General Practice, Jiangtai Community Health Service Center, Beijing, People’s Republic of China[9]Department of General Practice, Sanlitun Community Health Service Center, Beijing, People’s Republic of China[10]Department of General Practice, Zuojiazhuang Community Health Service Center, Beijing, People’s Republic of China[11]Department of General Practice, The First People’s Hospital of Chongwen District, Beijing, People’s Republic of China[12]Department of General Practice, Balizhuang Community Health Service Center, Beijing, People’s Republic of China[13]Department of General Practice, Majiapu Community Health Service Center, Beijing, People’s Republic of China[14]Department of Endocrinology, Beijing Aerospace General Hospital, Beijing, People’s Republic of China[15]Department of Endocrinology, China-Japan Friendship Hospital, Beijing, People’s Republic of China[16]Center of Endocrinology and Cardiovascular Disease, Department of Endocrinology, National Center of Cardiology and Fuwai Hospital, Beijing, People’s Republic of China
Objective: It is well known that diabetic kidney disease is a risk factor for cardiovascular diseases (CVD) in patients with type 2 diabetes mellitus (T2DM). In this study, the effects of urine albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR) on CVD outcomes were analyzed in a population of T2DM. Methods: The study was carried out using recorded information of a cohort study. A total of 1,914 patients with T2DM with no prevalent CVD were enrolled in an 8 years prospective study and received multifactorial intervention. The risk of CVD outcomes was assessed according to chronic kidney disease staging, which was categorized using AER (mg/d) and eGFR (mL/min/1.73 m(2)). The effects of AER and eGFR on risk of CVD onset were also analyzed. Results: During the follow-up period (median 6.8 years), 71 CVD events occurred. At baseline, those with AER >= 300 mg/d and coexisting eGFR 60-89 mL/min/ 1.73 m(2) or <60 mL/min/1.73 m(2) showed increased risk for CVD outcomes when compared with "no chronic kidney disease" (AER <30 mg/d and eGFR >= 90 mL/min/1.73 m(2)). The increased CVD risk was observed in patients who progressed to AER >= 30 mg/d during the follow-up period, whereas patients who progressed to eGFR <90 mL/min/1.73 m(2) alone showed no increased CVD risk. During the follow-up period, after multifactorial intervention, 8.7% patients with microalbuminuria and 1.8% patients with overt nephropathy reversed to nonnoalbuminuria or microalbuminuria. Conclusion: AER is a more sensitive predictor than eGFR for CVD outcomes in T2DM patients. Overt nephropathy can be reversed after multifactorial intervention.
基金:
Grant of Special Scientific Research on Capital Health Development [2016-1-2057, 2016-2-2054]; Beijing Municipal Science & Technology CommissionBeijing Municipal Science & Technology Commission [Z151100004015021]; International Diabetes Federation; University of Rochester's Clinical and Translational Science Award ([CTSA] from the National Center for Advancing Translational Sciences of the National Institutes of Health in USA) [UL1 TR000042, UL1 TR002001]
第一作者机构:[1]Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China
通讯作者:
通讯机构:[1]Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China[15]Department of Endocrinology, China-Japan Friendship Hospital, Beijing, People’s Republic of China[16]Center of Endocrinology and Cardiovascular Disease, Department of Endocrinology, National Center of Cardiology and Fuwai Hospital, Beijing, People’s Republic of China[*1]Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, 1 Dong Jiao Min Xiang, Beijing 100730, People’s Republic of China[*2]Department of Endocrinology, China-Japan Friendship Hospital, 167 Bei Li Shi Lu, Beijing 100029,People’s Republic of China
推荐引用方式(GB/T 7714):
Zhang Xue-Lian,Yuan Ming-Xia,Wan Gang,et al.The effects of AER and eGFR on outcomes of CVD in patients with T2DM in an urban community over 8 years of multifactorial treatment: the Beijing Communities Diabetes Study 18[J].THERAPEUTICS AND CLINICAL RISK MANAGEMENT.2018,14:1537-1545.doi:10.2147/TCRM.S170915.
APA:
Zhang, Xue-Lian,Yuan, Ming-Xia,Wan, Gang,Yang, Guang-Ran,Li, Dong-Mei...&Yuan, Shen-Yuan.(2018).The effects of AER and eGFR on outcomes of CVD in patients with T2DM in an urban community over 8 years of multifactorial treatment: the Beijing Communities Diabetes Study 18.THERAPEUTICS AND CLINICAL RISK MANAGEMENT,14,
MLA:
Zhang, Xue-Lian,et al."The effects of AER and eGFR on outcomes of CVD in patients with T2DM in an urban community over 8 years of multifactorial treatment: the Beijing Communities Diabetes Study 18".THERAPEUTICS AND CLINICAL RISK MANAGEMENT 14.(2018):1537-1545